|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Idenix Pharmaceuticals, Inc.
Corporate Headquarters
60 Hampshire Street
Cambridge
Massachusetts
02139
U.S.A.
Phone:
617-995-9800
Fax:
617-995-9801
|
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.
Email:
Ownership:
Public
Web Site:
Idenix Pharmaceuticals, Inc.
Employees:
200 + worldwide
Symbol: IDIX
|
|
|
Company News |
Idenix Pharmaceuticals, Inc. (IDIX) to Present at Three Upcoming Healthcare Conferences
5/9/2013 10:10:36 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Reports First Quarter 2013 Financial Results
5/1/2013 1:23:41 PM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting
4/24/2013 12:44:30 PM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Halts Development of Two Hepatitis C Treatments
2/5/2013 7:45:38 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Announces Collaboration With to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)
1/28/2013 9:09:21 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) May Drop Delayed Hep C Drug for New Versions
1/10/2013 8:10:31 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/3/2013 9:10:23 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for Study of Liver Diseases Annual Meeting
11/12/2012 8:00:57 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) Reports Third Quarter and Nine Month 2012 Financial Results and HCV Program Update
11/2/2012 7:39:53 AM
More...
|
Idenix Pharmaceuticals, Inc. (IDIX) to Host Conference Call Discussing Third Quarter and Nine Month 2012 Financial Results and HCV Program Update
10/26/2012 6:43:42 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|
|